ArticleBiomedicines2021

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.

Jangsoon Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.